| 摘要: |
| 目的探讨血清脑源性神经生长因子（BDNF）对首发精神分裂症患者早期改善的预测作用。方法选择90例女性首发精神分裂症患者为研究对象，给予利培酮治疗8周。在治疗前，治疗第2、8周末检测血清BDNF水平；采用阳性与阴性症状量表（PANSS）评定疗效，根据2周末PANSS减分率分为早期改善组51例（≥20%）和非早期改善组39例（＜20%）。选择同期45例女性健康者为正常对照组，检测其血清BDNF水平，与精神分裂症患者进行比较分析。结果与正常对照组比较，早期改善组治疗前、治疗第2周末血清BDNF水平均明显较低（均P＜0.01），治疗第8周末差异无统计学意义（P＞0.05）；与非早期改善组比较，治疗前，治疗第2、8周末血清BDNF水平均明显较高（均P＜0.05）。非早期改善组治疗前，治疗第2、8周末血清BDNF水平均明显低于正常对照组（均P＜0.01）。与自身治疗前比较，早期改善组和非早期改善组第2、8周末血清BDNF水平均明显升高（均P＜0.05）。经logistic回归分析，治疗前血清BDNF水平是治疗2周末早期改善的影响因素。治疗第8周末早期改善组治疗有效率为80.4%，明显高于非早期改善组的59.0%（P＜0.05）。结论首发精神分裂症患者存在BDNF异常降低，但经抗精神病药物治疗后明显改善，且治疗前BDNF水平对早期改善具有一定的预测作用。 |
| 关键词: 脑源性神经营养因子 精神分裂症 抗精神病药物 早期改善 |
| DOI： |
| 分类号: |
| 基金项目:湖州市科技局公益性技术应用研究项目 |
|
| Serum levels of brain derived neurotrophic factor in predicting early improvement of patients with first-episode schizophrenia |
|
FEI Xiaocong, CHEN Haizhi, YANG Shengliang, QIAN Mincai, SHEN Xinhua, CUI Lijun, LEI Lilei, SONG Baohua, ZHI Shengli, LI Jianhua
|
|
Huzhou Third Municipal Hospital
|
| Abstract: |
| Objective To investigate the predictive value of serum brain derived nerve growth factor (BDNF) for early improvement of patients with first-episode schizophrenia. Methods Ninety female patients with first-episode schizophrenia receiving risperidone treatment for 8 weeks (study group) and 45 healthy females (control group) were enrolled in the study. Serum BDNF levels were measured before and 2, 8 weeks after treatment. The positive and negative symptoms scale (PANSS) was evaluated before and after treatment to assess the efficacy. According to results at 2 weeks after treatment, the PANSS scores were reduced ≥20% in 51 cases (early improvement group) and reduced＜20% in 39 cases (non-early improvement group. Results Compared with control group, serum BDNF levels in early improvement group were significantly lower than those before treatment and 2 weeks after treatment (both P＜0.01), however, there was no difference at 8 weeks of treatment (P ＞0.05). Compared with the non-early improvement group, serum BDNF levels were significantly higher in early improvement group before and 2, 8 weeks after treatment (P ＜0.05). Serum BDNF levels of non-early improvement group before and 2, 8 weeks after treatment were significantly lower than those in normal control group (both P＜0.01). Compared with those before treatment, serum BDNF levels in early improvement group and non-early improvement group at 2, 8 weeks
after treatment were significantly increased (both P＜0.05). Logistic regression analysis showed that serum BDNF level before treatment was the influencing factor for the early improvement. The effective rate of the early improvement group in 8 weeks of treatment was significantly higher than that of the non-early improvement group (80.4% vs 59.0%, P＜0.05). Conclusion The level of BDNF before treatment can be used as a predictive marker for the early improvement in patients with first-episode schizophrenia. |
| Key words: Brain derived neurotrophic factor Antipsychotic drug Schizophrenia Early improvement |
